Asset Details
Do you wish to reserve the book?
Gallium Liquid Metal Nanoparticles as Agents to Treat Multidrug‐Resistant Bacterial Infections
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Gallium Liquid Metal Nanoparticles as Agents to Treat Multidrug‐Resistant Bacterial Infections
Do you wish to request the book?
Gallium Liquid Metal Nanoparticles as Agents to Treat Multidrug‐Resistant Bacterial Infections
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Gallium Liquid Metal Nanoparticles as Agents to Treat Multidrug‐Resistant Bacterial Infections
2025
Overview
Multidrug‐resistant (MDR) bacterial infections constitute one of the top global public health threats. This study investigated the potential of gallium liquid metal nanoparticles (GaLM NPs) as a new agent against MDR pathogens. GaLM NPs was bactericidal against methicillin‐resistant Staphylococcus aureus (MRSA) isolates and a vancomycin‐intermediate S. aureus reference strain (minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values between 39 and 156 μg/mL). The bactericidal activity of GaLM NPs was supported by transmission electron microscopy showing marked ultrastructural changes in the cell envelope of MRSA USA300. GaLM NPs were bacteriostatic against selected Gram‐negative (Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae) reference strains and isolates (MICs between 39 and 625 μg/mL). Furthermore, GaLM NPs demonstrated additive and bacteriostatic activity when combined with sub‐inhibitory concentrations of colistin against P. aeruginosa isolates. Additionally, GaLM NPs showed anti‐biofilm activity against MRSA USA300 (minimum biofilm eradication concentration of 625 μg/mL); morphology changes of GaLM NPs‐treated cells was demonstrated by scanning electron microscopy. Finally, GaLM NPs was safe to human epidermal keratinocyte cell line at 1024 µg/mL (6.5 × MIC). We conclude that GaLM NPs warrant further exploration for the effective treatment of Gram‐positive or Gram‐negative infections both alone and in combination with antimicrobial drugs. Gallium liquid metal nanoparticles (GaLM NPs) are promising agents for treating multidrug‐resistant Gram‐positive and Gram‐negative bacterial infections.(A), Preparation of GaLM NPs suspension; (B, C), Morphology of GaLM NPs without and with F127, scale bar: 500 nm; (D), Diameter distribution of GaLM NPs; (E), TEM showing effects of GaLM NPs treatment on morphology of MRSA USA300; (F), SEM showing eradication of MRSA USA 300 biofilms by GaLM NPs.
Publisher
John Wiley & Sons, Inc,Wiley
Subject
Acinetobacter baumannii - drug effects
/ Anti-Bacterial Agents - pharmacology
/ Biofilms
/ Colistin
/ Drug Resistance, Multiple, Bacterial - drug effects
/ Gallium
/ gallium liquid metal nanoparticles, antimicrobial resistance
/ Gram-Negative Bacteria - drug effects
/ Humans
/ Klebsiella pneumoniae - drug effects
/ Metal Nanoparticles - chemistry
/ Methicillin-Resistant Staphylococcus aureus - drug effects
/ Microscopy, Electron, Transmission
/ Minimum inhibitory concentration
/ Multidrug resistant organisms
/ Pseudomonas aeruginosa - drug effects
/ Scanning electron microscopy
